Sunovion CTH-302 – Oral Apomorphine vs. Apomorphine injection.

The aim of this research is to see how movement may be improved by taking oral Apomorphine and evaluate this method of delivery against the sub-cutaneous injection of Apomorphine which is currently available for people with Parkinson’s.

Who

25 people diagnosed with Parkinson’s.  You must have a good response to Levodopa, which you should be taking at least 3 times a day and experience “OFF” periods.

What

You will first go through a screening process where you will be assessed for your suitability to take part in the full research trial.  At this screening visit you will have the opportunity to ask questions, give your consent, and a range of assessments will be performed.

You will be required to take both oral Apomorphine and subcutaneous Apomorphine injection during the course of the study.

For full information about the research:

Please read the Participant Information Sheet. 

If you would like to understand more about the trial visit structure, read the trial flow diagram.

Deadline
Funded by

Sunovion Pharmaceuticals Inc.

Research
  • Biological samples
  • Treatments or therapies
Locations
Location

Kings College Hospital
Denmark Hill
Parkinson's research facility
London
SE5 9RT
United Kingdom

Contact

Aleksandra or Dhaval

0203 299 7154

[email protected] or [email protected]

Location

Imperial College Healthcare NHS Trust
Charing Cross Hospital
Fulham Road
Hammersmith
W6 8RF
United Kingdom

Contact

Agnes Motsi

0203 3111 714

[email protected] 

Location

Queens medical centre Nottingham university hospitals NHS trust
Derby Road
Nottingham
NG7 2UH
United Kingdom

Contact

Julie Lynch

[email protected]

01159249924 ext 66517